Dinner Short Course*

The dinner short course is designed to be instructional, interactive and provide in-depth information. It allows for one-on-one interaction and provides a great way to explain more technical aspects that would otherwise not be covered during our main presentations. Attendees enjoy dinner with each short course as part of their registration.

Wednesday, September 27, 2017 | 7:00 pm ­— 9:30 pm

SC14: Commercialization of Ophthalmic Drugs and Devices

The course is designed to cover the basic tenets needed to successfully commercialize drugs and devices in the ophthalmic space. Topics covered include: 1. Company/Business strategy and funding, 2. Preparing for commercial launch, 3. Ophthalmic drug  pricing, and 4. KOL interaction. There will also be a question and answer session with leaders in ophthalmology experienced in launching ophthalmic start-ups.

Rough Agenda

7pm Welcome attendees and dinner

Course moderator: Emmett Cunningham, Partner, Clarus Ventures

7:00 Company/Business strategy and Funding; Preparing for commercial launch; and KOL interaction

Rick Beckman, M.D., CMO, Clearside Biomedical, Inc.

Brion Raymond, Independent Commercialization Strategy Consultant

8:30 Q&A with all speakers

Emmett Cunningham, Partner, Clarus Ventures

Glenn Noronha, Ph.D., CSO, Clearside Biomedical, Inc.

Rick Beckman, M.D., CMO, Clearside Biomedical, Inc.

Brion Raymond, Independent Commercialization Strategy Consultant

9:30 Close of short course

 

 

Instructors:

Emmett Cunningham, Partner, Clarus Ventures

Glenn Noronha, Ph.D., CSO, Clearside Biomedical, Inc.

Rick Beckman, M.D., CMO, Clearside Biomedical, Inc.

Brion Raymond, Independent Commercialization Strategy Consultant

 

 

Instructor Bios

 Emmett Cunningham, Partner, Clarus Ventures

Dr. Cunningham joined Clarus in 2006 with extensive experience in the biomedical and biopharmaceutical sectors. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. He is Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology at the Wilmer Eye Institute in Baltimore.

 Glenn Noronha, Ph.D., CSO, Clearside Biomedical, Inc.

Glenn Noronha has 20 years of experiences following post-secondary education and training. He has held progressive leadership positions in large and small biotech and pharma companies including two start-ups; his experiences span clinical and nonclinical development with expertise in both biologicals and small molecules. Currently he is CSO at Clearside Biomedical, Inc. Previously, he held leadership positions at Sucampo, Novartis/Alcon, and TargeGen.

 Rick Beckman, M.D., CMO, Clearside Biomedical, Inc.

Dr. Beckman is a board certified ophthalmologist who brings 13 years of clinical practice experience and over 20 years of corporate executive and consultancy experience within the global ophthalmic industry to Clearside. Prior to joining Clearside, Dr. Beckman managed a successful pharmaceutical and medical device industry consulting firm that served a broad range of companies. Previously, he held the position of Chief Medical Officer and General Manager of the Ocular and Novel Drug Delivery Systems business unit at Unilife Corporation. He has also held senior leadership roles with Ophthotech Pharmaceuticals, Neurotech Pharmaceuticals, Alcon Laboratories, Lux Pharmaceuticals and Becton-Dickinson. Dr. Beckman received his medical degree from the University of Michigan, and practiced as a glaucoma specialist for three years in academic practice at North Shore University Hospital-Cornell University Medical College, and for ten years in private practice following an ophthalmology residency at Henry Ford Hospital and a Glaucoma Fellowship at Harvard University.

 Brion Raymond, Independent Commercialization Strategy Consultant

Brion entered the ophthalmology industry in 2002 when he joined Carl Zeiss Meditec and launched a 2nd generation frequency doubling perimeter and the StratusOCT into glaucoma. In 2004, he joined Genentech and led brand strategy and thought leader engagement through the launch of Lucentis. After six years on the Lucentis team, and holding various leadership roles in marketing, sales and commercial operations, he was promoted to Marketing Director for Erivedge, an orphan skin cancer drug, which he launched in 2012. After ten years at Genentech, he moved to small biotech and has been leading the transformation of clinical stage companies as they prepare for their first commercial launch. At XOMA, he designed and built commercial capabilities to support a launch in non-infectious uveitis. While there, he also led a revamp of XOMA’s corporate strategy, including pipeline optimization, business development opportunity assessment and internal resource alignment to support the long-term growth of the company. After a failed Phase III trial, however, he moved to Dynavax where he helped lead the preparations for the launch of their first commercial molecule, which ultimately ended with a CRL from the FDA in late 2016. Since January, Brion has been consulting for a variety of early-stage biotech companies in ophthalmology and oncology as they develop their commercial strategy and goals. His projects include developing and validating target product profiles, creating valuation models, pursuing innovative reimbursement approaches and building thought leader engagement and communication strategies. Brion holds a BS degree in Optics from the University of Rochester and an MBA from the Tuck School of Business at Dartmouth College.

 

 

*Separate Registration Required.